Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection period, people often have mild or no symptoms. Early symptoms can include fever, dark urine, abdominal pain, and yellow tinged skin. The virus persists in the liver, becoming chronic, in about 70% of those initially infected. Early on, chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop serious complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.
Hepatitis E is inflammation of the liver caused by infection with the hepatitis E virus (HEV); it is a type of viral hepatitis. Hepatitis E has mainly a fecal-oral transmission route that is similar to hepatitis A, although the viruses are unrelated. HEV is a positive-sense, single-stranded, nonenveloped, RNA icosahedral virus and one of five known human hepatitis viruses: A, B, C, D, and E.
Adenoviruses are medium-sized, nonenveloped viruses with an icosahedral nucleocapsid containing a double-stranded DNA genome. Their name derives from their initial isolation from human adenoids in 1953.
Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent infection with relatively rapid onset, or in chronic form, typically progressing from a long-lasting asymptomatic condition up to a decompensated hepatic disease and hepatocellular carcinoma (HCC).
Hepatitis B is an infectious disease caused by the Hepatitis B virus (HBV) that affects the liver; it is a type of viral hepatitis. It can cause both acute and chronic infection.
A hepatitis C vaccine, a vaccine capable of protecting against the hepatitis C virus (HCV), is not yet available. Although vaccines exist for hepatitis A and hepatitis B, development of an HCV vaccine has presented challenges. No vaccine is currently available, but several vaccines are currently under development.
Alisporivir (INN), or Debio 025, DEB025, is a cyclophilin inhibitor. Its structure is reminiscent of, and synthesized from ciclosporin.
Hepatitis B virus (HBV) is a partially double-stranded DNA virus, a species of the genus Orthohepadnavirus and a member of the Hepadnaviridae family of viruses. This virus causes the disease hepatitis B.
Jane A. McKeating is a professor of molecular biology at Oxford University, and honorary professor at the University of Birmingham, England, where she worked as a professor of molecular virology until 2017. She is listed as a notable scientist in Thomson Reuters' Highly Cited Researchers 2014, ranking her among the top 1% most cited scientists.
Sir Adrian Vivian Sinton Hill, is a British-Irish vaccinologist who is Director of the Jenner Institute and Lakshmi Mittal and Family Professor of Vaccinology at the University of Oxford, an honorary Consultant Physician in Infectious Diseases, and Fellow of Magdalen College, Oxford. Hill is a leader in the field of malaria vaccine development and was a co-leader of the research team which produced the Oxford–AstraZeneca COVID-19 vaccine, along with Professor Sarah Gilbert of the Jenner Institute and Professor Andrew Pollard of the Oxford Vaccine Group.
Elbasvir/grazoprevir, sold under the brand name Zepatier, is a fixed-dose combination for the treatment of hepatitis C, containing elbasvir and grazoprevir. It is used to treat chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in both treatment-naïve and treatment-experienced patients.
Helen Irene McShane is a British infectious disease physician and a professor of vaccinology, in the Jenner Institute at the University of Oxford, where she has led the tuberculosis vaccine research group since 2001. She is senior research fellow at Harris Manchester College, Oxford.
Dame Sarah Catherine Gilbert FRS is an English vaccinologist who is a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. She specialises in the development of vaccines against influenza and emerging viral pathogens. She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011.
Katie Jane Ewer is a British immunologist and Professor of Vaccine Immunology at the University of Oxford's Jenner Institute.
A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.
Susanna Jane Dunachie is a British microbiologist who is Professor of Infectious Diseases at the University of Oxford. Her work considers microbiology and immunology to better understand bacterial infection and accelerate the development of vaccines. She has focused on melioidosis, scrub typhus and tuberculosis. During the COVID-19 pandemic, she studied T cell immunity to severe acute respiratory syndrome coronavirus 2.
Christine Rollier is a French immunologist who is a professor at the University of Surrey. She focusses on the development of vaccines to treat infectious diseases. In particular, Rollier has focussed on the development of vaccinations to eliminate the plague.
Deborah F. Kelly is an American biomedical engineer who is a professor at Pennsylvania State University. Her research makes use of cryogenic electron microscopy to better understand human development and disease. She serves as President of the Microscopy Society of America.
Lucy Chappell is a British professor of obstetrics at King’s College London and the Chief Scientific Adviser (CSA) for the UK Department of Health and Social Care. As part of her CSA role, she oversees the National Institute for Health and Care Research (NIHR) as Chief Executive Officer. Her research areas include medical problems during pregnancy such as pre-eclampsia, and the safety of medicines in pregnancy.
Catherine Ann Malcolm Stedman is a New Zealand pharmacologist and gastroenterologist, and is a clinical professor at the University of Otago, specialising in hepatitis C drug development. She is the first woman gastroenterologist to become a professor of medicine in New Zealand.
